$NUVB

Nuvation Bio's Chief Regulatory Officer, Kerry Wentworth, sold 36,750 shares of Class A Common Stock for $184,279 after exercising stock options. The sale was executed under a pre-arranged 10b5-1 plan. This transaction follows a significant 158.59% return for Nuvation Bio shares over the past year, and the company has recently made important strides with an amended license agreement for safusidenib and the European Medicines Agency's validation of taletrectinib.